Repository logo
 

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Abstract

Abstract available in pdf.

Description

CAPRISA, 2018.

Keywords

Adolescent., Adult., Anti-HIV Agents/adverse effects., Anti-HIV Agents/blood., Anti-HIV Agents/pharmacokinetics.

Citation

Landovitz, R.J., Li, S., Grinsztejn, B., Dawood, H., Liu, A.Y., Magnus, M., Hosseinipour, M.C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M., Hendrix, C.W., Eshleman, S.H., Zhang, Y., Tolley, E., Sugarman, J., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A.R., Margolis, D., Spreen, W.R., Cohen, M.S., McCauley, M.and Eron, J.J. 2018. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Medicine 15(11), e1002690.

DOI